# Jessicca Rege

> Jessicca M. Rege, Ph.D. is the Chief Executive Officer of Sus Clinicals, Inc., a biotech accelerating cancer drug development through the Oncopig Cancer Model, an FDA-cleared, genetically engineered pig platform for preclinical testing. A pharmaceutical scientist with more than 15 years in oncology R&D and global medical affairs, she previously served as Chief Development Officer at Mural Oncology, where she helped lead the company's public offering, and as VP, Head of Clinical Development, Oncology at Alkermes. She holds a Ph.D. in pharmaceutical sciences with a focus on pharmacogenomics from Virginia Commonwealth University.

- **Role:** Chief Executive Officer at Sus Clinicals, Inc.
- **Organizations:** Sus Clinicals, Inc., Mural Oncology, Alkermes, OncXerna Therapeutics, Daiichi-Sankyo, Eli Lilly, Eisai Inc., Hoffman-LaRoche, Bristol Myers Squibb
- **Nationality:** United States
- **Education:** Ph.D., Pharmaceutical Sciences (pharmacogenomics), Medical College of Virginia, Virginia Commonwealth University, M.S., Physiology, Virginia Commonwealth University, B.A., Biology, Carson-Newman College
- **Known for:** Appointed Chief Executive Officer of Sus Clinicals effective August 1, 2024 after an extensive board search, As Chief Development Officer, helped lead Mural Oncology through its public offering, At OncXerna, helped build company infrastructure and raised a $16M Series A and $80M Series B

## Career timeline

- **Early career** — Clinical research positions at Hoffman-LaRoche and Bristol Myers Squibb
- **Mid career** — Senior Director, Head of Global Medical Affairs - Oncology at Eisai Inc.
- **Mid career** — Associate VP, Global Clinical Collaborations - Oncology at Eli Lilly
- **Mid career** — Global Chief of Staff - Cancer Enterprise at Daiichi-Sankyo
- **Mid career** — Global Chief Development Officer at OncXerna; raised Series A ($16M) and Series B ($80M)
- **2020** — Joined Alkermes as VP, Head of Clinical Development, Oncology; built immuno-oncology strategy
- **2023** — Chief Development Officer at Mural Oncology; helped lead the company's public offering
- **2024** — Appointed CEO of Sus Clinicals, Inc., effective August 1, 2024

## Achievements

- Appointed Chief Executive Officer of Sus Clinicals effective August 1, 2024 after an extensive board search
- As Chief Development Officer, helped lead Mural Oncology through its public offering
- At OncXerna, helped build company infrastructure and raised a $16M Series A and $80M Series B
- Established Alkermes' immuno-oncology development strategy and oversaw global clinical trials
- More than 15 years of leadership across oncology R&D and global medical affairs

## Latest updates

- **2024-08** — Became CEO of Sus Clinicals, Inc.
- **2025-04** — Featured on the 'She Leads Biotech' podcast discussing her path from big pharma to biotech and the science of the Oncopig.
- **2025-09** — Featured discussing leadership in life sciences on The Pharmaverse via Sus Clinicals' LinkedIn.

## Links

- Website: https://susclinicals.com
- LinkedIn: http://www.linkedin.com/in/jessiccarege
- Twitter/X: https://twitter.com/susclinicals
- YouTube: https://www.youtube.com/playlist?list=PLlAFUt37S72riEAXOhdkCNFvau3b3u0Ao
- Facebook: https://www.facebook.com/Sus-Clinicals-104608361626141

---

Profile page: https://yespress.io/jessicca-rege
Published by YesPress — https://yespress.io
Last updated: 2026-07-01